Literature DB >> 33576707

Docetaxel/dimethyl-β-cyclodextrin inclusion complexes: preparation, in vitro evaluation and physicochemical characterization.

Bhupendra Raj Giri1, Jaehyeok Lee1, Dong Yu Lim2, Dong Wuk Kim1.   

Abstract

Despite the development in novel drug delivery techniques and synthesis of multifunctional excipients, oral delivery of hydrophobic drug like docetaxel (DTX) is still challenging. The present work investigates the inclusion complexation of DTX, and dimethyl-β-cyclodextrin (DM-β-CD) to improve the solubility, dissolution and permeability of the drug. Amongst the native and modified β-cyclodextrins, DM-β-CD showed the highest solubility of DTX. Solid binary inclusion complex (IC) of DTX with DM-β-CD was prepared by solvent evaporation technique and thoroughly characterized for solubility, dissolution, permeability, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR) and nuclear magnetic resonance (1H NMR). The aqueous solubility and in vitro dissolution rate of DTX/DM-β-CD IC were markedly increased by 76.04- and 3.55-fold compared to free DTX powder. The permeability of DTX/DM-β-CD IC showed similar absorptive permeability but decreased efflux from the absorbed DTX, compared to pure DTX. Further, physicochemical studies of IC revealed the change of crystalline state DTX to its amorphous form. Moreover, FT-IR and 1H NMR results indicate the formation of true inclusion complex between DTX and DM-β-CD at 1:1 molar ratio. Collectively, solid inclusion complexes prepared by spray drying method can be an effective strategy to enhance the biopharmaceutical performance of a highly hydrophobic drug DTX.

Entities:  

Keywords:  Docetaxel; cyclodextrin; dissolution; inclusion complexes; permeability; solubility

Year:  2021        PMID: 33576707     DOI: 10.1080/03639045.2021.1879840

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  5 in total

1.  Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology.

Authors:  Abdul Ahad; Yousef A Bin Jardan; Mohd Zaheen Hassan; Mohammad Raish; Ajaz Ahmad; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  nurP28, a New-to-Nature Zein-Derived Peptide, Enhances the Therapeutic Effect of Docetaxel in Breast Cancer Monolayers and Spheroids.

Authors:  Plinio Alejandro Trinidad-Calderón; Laura Margarita López-Castillo; Salvador Gallegos-Martínez; Grissel Trujillo-de Santiago; Silverio García-Lara; Mario Moisés Álvarez
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

3.  Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization, ex vivo and in vivo characterization.

Authors:  Qing Hu; Xiaoling Fu; Yanping Su; Yanfang Wang; Sihuan Gao; Xiaoqin Wang; Ying Xu; Changxi Yu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  A novel dual-prodrug carried by cyclodextrin inclusion complex for the targeting treatment of colon cancer.

Authors:  Lin Chen; Yan Lin; Zijun Zhang; Ruisheng Yang; Xiaosheng Bai; Zhongbing Liu; Zhongling Luo; Meiling Zhou; Zhirong Zhong
Journal:  J Nanobiotechnology       Date:  2021-10-19       Impact factor: 10.435

5.  Formulation of Genistein-HP β Cyclodextrin-Poloxamer 188 Ternary Inclusion Complex: Solubility to Cytotoxicity Assessment.

Authors:  Ameeduzzafar Zafar; Nabil K Alruwaili; Syed Sarim Imam; Omar Awad Alsaidan; Faisal K Alkholifi; Khalid Saad Alharbi; Ehab M Mostafa; Abdullah S Alanazi; Sadaf Jamal Gilani; Arafa Musa; Sultan Alshehri; Alenazy Rawaf; Ali Alquraini
Journal:  Pharmaceutics       Date:  2021-11-24       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.